Back to top
more

Lantheus (LNTH)

(Delayed Data from NSDQ)

$112.50 USD

112.50
643,774

+0.54 (0.48%)

Updated Oct 16, 2024 04:00 PM ET

After-Market: $112.50 0.00 (0.00%) 5:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (64 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Investors Heavily Search Lantheus Holdings, Inc. (LNTH): Here is What You Need to Know

Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Lantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Lantheus Holdings (LNTH) closed at $89.21, marking a -1.7% move from the previous day.

Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock

Zacks.com users have recently been watching Lantheus Holdings (LNTH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Lantheus Holdings (LNTH) Gains But Lags Market: What You Should Know

In the latest trading session, Lantheus Holdings (LNTH) closed at $83.83, marking a +0.5% move from the previous day.

Is It Worth Investing in Lantheus Holdings (LNTH) Based on Wall Street's Bullish Views?

Based on the average brokerage recommendation (ABR), Lantheus Holdings (LNTH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Lantheus Holdings (LNTH) Gains As Market Dips: What You Should Know

In the latest trading session, Lantheus Holdings (LNTH) closed at $82.40, marking a +1.22% move from the previous day.

Lantheus Holdings (LNTH) Dips More Than Broader Markets: What You Should Know

Lantheus Holdings (LNTH) closed the most recent trading day at $81.41, moving -1.26% from the previous trading session.

Lantheus and GlobalFoundries have been highlighted as Zacks Bull and Bear of the Day

Lantheus and GlobalFoundries are part of the Zacks Bull and Bear of the Day article.

Kevin Cook headshot

Bull of the Day: Lantheus (LNTH)

Medical diagnostics leader in prostate cancer is driving 34% sales and 32% EPS growth

Teleflex's (TFX) Urolift Global Expansion Aids Amid Cost Woes

Teleflex's (TFX) vascular and interventional access product portfolios witness accelerated growth following the $976-million acquisition of Vascular Solutions.

Labcorp (LH) Announces Completion of the Fortrea Spin-off

Labcorp (LH) completes the planned spin-off of Fortrea to operate as an independent clinical development business.

Acadia Healthcare (ACHC) Inks JV to Better Serve New Hampshire

Acadia Healthcare (ACHC) enters into a JV with New Hampshire-based SolutionHealth to build a behavioral health facility and address the dire need for advanced behavioral health services across the state.

Bruker (BRKR) Launches the SciY Platform of Software Solutions

Bruker's (BRKR) SciY platform provides many digital end-to-end solutions for life science research and development, manufacturing automation and QC.

Lantheus Holdings (LNTH) Gains But Lags Market: What You Should Know

In the latest trading session, Lantheus Holdings (LNTH) closed at $83.92, marking a +1.17% move from the previous day.

Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe

Myriad Genetics' (MYGN) collaboration with medical imaging provider, SimonMeD, is expected to advance precision medicine with a new hereditary cancer assessment program.

Abbott (ABT) Teams Up With the ADA to Evaluate CGM Systems

Abbott (ABT) and ADA are going to offer personalized, therapeutic nutrition for diabetes people using CGM systems.

Lantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should Know

Lantheus Holdings (LNTH) closed at $82.95 in the latest trading session, marking a -1.88% move from the prior day.

BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology

The foundation of BioSig's (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.

OrthoPediatrics (KIDS) Unveils GIRO for Pediatric Orthopedics

The GIRO Growth Modulation System by OrthoPediatrics (KIDS) introduces a tether device designed specifically for pediatric patients.

Integra (IART) Completes Enrollment in the DuraSorb IDE Study

Integra (IART) announces the completion of patient enrollment in the DuraSorb IDE clinical study.

Derek Lewis headshot

3 Top-Ranked Mid-Caps With Big Growth

Mid-caps provide a nice blend of growth potential paired with a more established nature, undoubtedly a solid pairing. Is it time for investors to take a closer look at these three?

Bruker (BRKR) Introduces the D6 PHASER Benchtop XRD Platform

Bruker's (BRKR) new D6 PHASER platform is to be used for material analysis and advanced research.

Abbott (ABT) EPD Sales Aid Growth Amid Currency Headwind

Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.

Investors Heavily Search Lantheus Holdings, Inc. (LNTH): Here is What You Need to Know

Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Organigram (OGI) Grows in Cannabis Space With SHRED X Heavies

Organigram's (OGI) SHRED X Heavies is not only the first infused pre-roll in the SHRED product portfolio but also joins a lineup of value-driven, convenient and bold-flavored offerings.